COMP <GO>
IMVT vs SRRK // REVENUE GROWTH (YOY)
Immunovant Inc. (NASDAQ) VS. Scholar Rock Holding Corporation (NASDAQ) • 15-METRIC TALLY: IMVT 3
— SRRK 4
▲ REVENUE GROWTH (YOY) LEADER: IMVT
LAST: $29.04 (+2.22%) • MKT CAP: $5.87B
revenue-growth
9.90%
LAST: $43.98 (+2.49%) • MKT CAP: $5.23B
revenue-growth
7.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IMVT VS. SRRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IMVT | SRRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.65% | -5.59% | -1.06 | SRRK | /fcf-yield <GO> |
| Operating Margin | -36.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -29.50% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 9.90% | 7.70% | +2.20 | IMVT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 13.67 | +12.33 | IMVT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 5/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 36.4 | 44.5 | -8.10 | SRRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.98 | 1.02 | -0.04 | SRRK | /macro-sensitivity <GO> |
| Forward P/E Multiple | 36.0x | 32.0x | +4.00 | SRRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.87B | $5.23B | $642.4M | IMVT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IMVT REV | SRRK REV | IMVT GROSS % | SRRK GROSS % | IMVT FCF | SRRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.67B | $1.08B | — | — | -$407.3M | -$300.6M |
| FY 2024 | $1.37B | $705.8M | — | — | -$376.6M | -$201.0M |
| FY 2023 | $856.8M | $479.6M | — | — | -$214.2M | -$145.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IMVT // BETA 0.98
SRRK // BETA 1.02